Company / Capital Expenditures
REGENXBIO Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.4M
FY2025
5-year range
$2.4M / $30.7M
FY2021-FY2025
Trend
-0.9%
vs FY2024
Sector context
#90 of 194
Health Care
What the data says
At $2M, REGENXBIO Inc.'s capital expenditures ranks #90 of 194 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $31M in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -28.9%.
Declined from $10M to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -57.2%
- 5-Year CAGR
- -28.9%
- 10-Year CAGR
- -
Sector benchmark
#90 of 194 in Health CareTop 46% of 194This company $2.4M Sector average $117.5M
▼
-97.9% below sector average
Key checks
Key Insights
- REGENXBIO Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -28.9%, indicating a declining trend.
- In FY2025, capital expenditures decreased 0.9% year-over-year.
- Ranks #90 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -0.9% |
| FY2024 | $2.4M | -75.5% |
| FY2023 | $10.0M | -67.6% |
| FY2022 | $30.7M | +162.2% |
| FY2021 | $11.7M | -11.7% |
| FY2020 | $13.3M | +85.4% |
| FY2019 | $7.2M | -46.1% |
| FY2018 | $13.3M | +85.4% |
| FY2017 | $7.2M | +1271.6% |
| FY2016 | $522.0K | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026